Hoth Therapeutics (HOTH) Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
HOTH Community Fair Values
Create NarrativeSee what 146 others think this stock is worth. Follow their fair value or set your own to get alerts.
Hoth Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.31 |
| 52 Week High | US$3.80 |
| 52 Week Low | US$0.66 |
| Beta | 0.64 |
| 1 Month Change | -14.38% |
| 3 Month Change | 4.80% |
| 1 Year Change | 48.69% |
| 3 Year Change | -67.49% |
| 5 Year Change | -96.92% |
| Change since IPO | -99.39% |
Recent News & Updates
Recent updates
Hoth Therapeutics (NASDAQ: HOTH): Small-Cap Biotech Pairing Clinical Breakthroughs with AI Innovation
Sep 08
Weekly Picks: 💸 A fintech heavyweight with even more upside potential and 2 more picks
Sep 05
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury
Sep 20Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule
Jun 29Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation
Nov 12We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate
Jun 10Shareholder Returns
| HOTH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.4% | 5.1% | -1.6% |
| 1Y | 48.7% | 7.0% | 14.4% |
Return vs Industry: HOTH exceeded the US Pharmaceuticals industry which returned 3.5% over the past year.
Return vs Market: HOTH exceeded the US Market which returned 17.2% over the past year.
Price Volatility
| HOTH volatility | |
|---|---|
| HOTH Average Weekly Movement | 10.6% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HOTH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HOTH's weekly volatility has decreased from 30% to 11% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 3 | Robb Knie | hoththerapeutics.com |
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer’s or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus.
Hoth Therapeutics, Inc. Fundamentals Summary
| HOTH fundamental statistics | |
|---|---|
| Market cap | US$17.50m |
| Earnings (TTM) | -US$10.01m |
| Revenue (TTM) | n/a |
Is HOTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HOTH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.01m |
| Earnings | -US$10.01m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did HOTH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/05 05:00 |
| End of Day Share Price | 2025/11/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hoth Therapeutics, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |